|
PRESS RELEASE
Nicholas Piramal Secures
Product Patent from US Patent & Trademark Office for its
Cyclin-Dependent Kinase (CDK) inhibitors
Dr.
Noopur Raje from Dana Faber Cancer Institute presenting on
NPIL’s lead compound P-276-00 at 49th American Society of
Hematology Conference at Atlanta, USA
Mumbai, India 10 December 2007:
Nicholas Piramal India Limited (NPIL) announced today that the
US Patent & Trademark office has granted Product Patent to
NPIL. The granted claims of the patent cover the novel
compounds, including NPIL’s clinical candidate P-276-00, and
processes for their preparation. These compounds are being
developed as therapeutic agents useful in the treatment of
cancer.
Earlier NPIL has been granted a patent in South Africa for its
CDK inhibitors. NPIL has related national phase applications
in 14 other countries. The Company has filed five other patent
applications covering different aspects of its CDK inhibitors.
Dr. Noopur Raje from Dr. Ken Anderson group from Dana Faber
Cancer Institute is giving an oral presentation today at 49th
Annual Meeting and Exposition of American Society of
Hematology (ASH) being held at Atlanta, Georgia in U.S. from
December 8-10, 2007. They have carried out independent studies
on NPIL’s lead compound P-276-00 in Multiple Myeloma and will
be presenting new data on its pre-clinical studies.
The ASH Annual Meeting is the premier forum for physicians and
researchers to hear the most up-to-date developments in
Hematology. The event attracts over 16,000 Hematologists and
other health-care professionals from 100 countries around the
world.
Dr. (Mrs.) Swati Piramal, Director – Strategic Alliances &
Communications, NPIL said, "The presentation of data on
pre-clinical studies at annual conference of American Society
of Hematology marks an important milestone for development of
NPIL’s Oncology compound."
For further information contact:
Notes to editors:
About Nicholas Piramal India Limited:
Nicholas Piramal India Limited ("NPIL") is one of India's
largest pharmaceutical companies with a growth track record of
above 30% CAGR since 1988. The Company is currently ranked 4th
in the Indian market with a diverse product portfolio spanning
nine therapeutic areas. NPIL's had consolidated Revenues of Rs.
24.7 billion in 2006-07. The Company has R&D capabilities in
Custom Chemical Synthesis, Process Innovation, NDDS and Basic
Research. It has world-class USFDA-approved formulations and
API facilities without any 483s.
NPIL has a long track record of successful collaboration with
innovator companies. Since 2003, the Company has made
significant investments to become a global custom
manufacturing organisation (“CMO") for large and medium-sized
innovator companies. Nicholas Piramal has a global CMO
footprint across North America, Europe & Asia, and is
committed to respecting Intellectual Property.
NPIL is listed in India on the Bombay Stock
Exchange and National Stock Exchange. For further information,
please mail
investorrelations@nicholaspiramal.co.in
or visit
www.nicholaspiramal.com.
|
